Form 4: Acadia Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Acadia Pharmaceuticals' EVP, Chief Commercial Officer, Thomas Garner, received stock options and restricted stock units as part of the 2024 Equity Incentive Plan.

Summary

• Thomas Garner, the Executive Vice President and Chief Commercial Officer of Acadia Pharmaceuticals, was granted stock options and restricted stock units on December 9, 2024.
• The stock options allow Garner to purchase 235,849 shares of common stock at a price of $18.76 per share.
• 25% of the stock options will vest on December 9, 2025, with the remaining options vesting in 36 equal monthly installments thereafter.
• Garner also received 45,372 restricted stock units, each representing a contingent right to receive one share of Acadia's common stock.
• 50% of the restricted stock units will vest on December 9, 2026, and 25% will vest on each of December 9, 2027, and December 9, 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns executive interests with shareholder value. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The equity grants are part of the company's 2024 Equity Incentive Plan.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules are also typical, designed to align executive interests with long-term company performance.
• Companies like Biogen, Amgen, and Gilead Sciences also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize executive performance and long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, vesting, executive compensation, Acadia Pharmaceuticals, Thomas Garner